The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Shenouda Maged since 2015.
This trader's CIK number is 1658369.
At the time of last reporting, Shenouda Maged was the Chief Financial Officer of Relmada Therapeutics, Inc.. (stock ticker symbol RLMD).
Also see all insider trading activities at Relmada Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | RLMD | 200,000 | $97,190 | 0 | $0 | 0 | $0 |
| 2024 | RLMD | 86,107 | $275,418 | 0 | $0 | 0 | $0 |
| 2021 | RLMD | 0 | $0 | 33,000 | $1,156,389 | 33,000 | $1,389,959 |
| 2019 | RLMD | 978 | $22,494 | 0 | $0 | 0 | $0 |
| 2015 | RLMD | 5,000 | $14,750 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2018 | AZRX | 20,000 | $26,220 | 0 | $0 | 0 | $0 |
1. Relmada Therapeutics, Inc. (RLMD)
2. Entero Therapeutics, Inc. (AZRX)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-05-19 | RLMD | Buy | 90,000 | .48 | 43,650 |
| 2025-05-20 | RLMD | Buy | 60,000 | .52 | 31,440 |
| 2025-05-16 | RLMD | Buy | 50,000 | .44 | 22,100 |
| 2024-09-09 | RLMD | Buy | 8,194 | 2.55 | 20,894 |
| 2024-09-10 | RLMD | Buy | 21,118 | 2.73 | 57,652 |
| 2024-09-11 | RLMD | Buy | 24,120 | 2.95 | 71,154 |
| 2024-01-31 | RLMD | Buy | 6,875 | 4.07 | 27,946 |
| 2024-01-30 | RLMD | Buy | 15,000 | 3.89 | 58,320 |
| 2024-01-29 | RLMD | Buy | 10,800 | 3.65 | 39,452 |
| 2021-03-08 | RLMD | Option Ex | 10,000 | 3.24 | 32,400 |
| 2021-03-08 | RLMD | Sale | 100 | 35.00 | 3,500 |
| 2021-03-09 | RLMD | Sale | 7,527 | 35.72 | 268,871 |
| 2021-03-10 | RLMD | Sale | 2,373 | 35.11 | 83,313 |
| 2021-02-11 | RLMD | Option Ex | 1,428 | 3.24 | 4,626 |
| 2021-02-11 | RLMD | Sale | 1,428 | 35.39 | 50,542 |
| 2021-02-08 | RLMD | Option Ex | 11,372 | 3.24 | 36,845 |
| 2021-02-08 | RLMD | Sale | 3,603 | 35.04 | 126,241 |
| 2021-02-09 | RLMD | Sale | 5,359 | 35.24 | 188,845 |
| 2021-02-10 | RLMD | Sale | 2,410 | 35.20 | 84,824 |
| 2021-02-02 | RLMD | Sale | 3,100 | 35.04 | 108,633 |
| 2021-02-02 | RLMD | Option Ex | 3,200 | 3.24 | 10,368 |
| 2021-02-03 | RLMD | Sale | 100 | 35.00 | 3,500 |
| 2021-01-27 | RLMD | Option Ex | 3,000 | 3.24 | 9,720 |
| 2021-01-27 | RLMD | Sale | 3,000 | 32.01 | 96,030 |
| 2021-01-26 | RLMD | Sale | 607 | 35.16 | 21,342 |
| 2021-01-25 | RLMD | Sale | 1,280 | 35.27 | 45,145 |
| 2021-01-22 | RLMD | Sale | 2,113 | 35.78 | 75,603 |
| 2021-01-22 | RLMD | Option Ex | 4,000 | 324.00 | 1,296,000 |
| 2019-10-21 | RLMD | Buy | 978 | 23.00 | 22,494 |
| 2015-12-15 | RLMD | Buy | 3,000 | 2.99 | 8,970 |
| 2015-12-14 | RLMD | Buy | 2,000 | 2.89 | 5,780 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2018-12-28 | AZRX | Buy | 20,000 | 1.31 | 26,220 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Shenouda Maged (Chief Financial Officer of Relmada Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.